Search results
Showing 586 to 600 of 888 results for community guidance
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.
This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.
Good practice guidance – Integrated process statement (PMG12)
This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
This quality standard covers providing and organising cancer services for babies, children and young people (from birth to 24 years, although the upper age limit may vary). It describes high-quality care in priority areas for improvement.
View quality statements for QS55Show all sections
Sections for QS55
- Quality statements
- Quality statement 1: Multidisciplinary teams for young people
- Quality statement 2: Access to clinical trials
- Quality statement 3: Electronic prescribing of chemotherapy
- Quality statement 4: Psychological and social support
- Quality statement 5: Neuro-rehabilitation
- Quality statement 6: Follow-up and monitoring of late effects
- Quality statement 7: Fertility support
Prevena incision management system for closed surgical incisions (MIB173)
NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing a pulmonary embolism (PE) or another deep vein thrombosis in adults.
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual
This quality standard covers assessing and treating fertility problems in people with explained and unexplained infertility, including access to IVF treatment. It also covers cryopreservation before cancer treatment that may affect fertility. It describes high-quality care in priority areas for improvement.
View quality statements for QS73Show all sections
Sections for QS73
- List of quality statements
- Quality statement 1: Lifestyle advice
- Quality statement 2: Referral for specialist consultation
- Quality statement 3: Counselling
- Quality statement 4: Semen analysis
- Quality statement 5: IVF for women under 40 years
- Quality statement 6: IVF for women aged 40 to 42 years
- Quality statement 7: Intracytoplasmic sperm injection
Specialist neonatal respiratory care for babies born preterm (NG124)
This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Tegaderm CHG securement dressing for vascular access sites (MIB231)
NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .